Literature DB >> 17848621

Erythrocyte glutamine depletion, altered redox environment, and pulmonary hypertension in sickle cell disease.

Claudia R Morris1, Jung H Suh, Ward Hagar, Sandra Larkin, D Anton Bland, Martin H Steinberg, Elliott P Vichinsky, Mark Shigenaga, Bruce Ames, Frans A Kuypers, Elizabeth S Klings.   

Abstract

Erythrocyte glutathione depletion has been linked to hemolysis and oxidative stress. Glutamine plays an additional antioxidant role through preservation of intracellular nicotinamide adenine dinucleotide phosphate (NADPH) levels, required for glutathione recycling. Decreased nitric oxide (NO) bioavailability, which occurs in the setting of increased hemolysis and oxidative stress, contributes to the pathogenesis of pulmonary hypertension (PH) in sickle cell disease (SCD). We hypothesized that altered glutathione and glutamine metabolism play a role in this process. Total glutathione (and its precursors) and glutamine were assayed in plasma and erythrocytes of 40 SCD patients and 9 healthy volunteers. Erythrocyte total glutathione and glutamine levels were significantly lower in SCD patients than in healthy volunteers. Glutamine depletion was independently associated with PH, defined as a tricuspid regurgitant jet velocity (TRV) of at least 2.5 m/s. The ratio of erythrocyte glutamine:glutamate correlated inversely to TRV (r = -0.62, P < .001), plasma arginase concentration (r = -0.45, P = .002), and plasma-free hemoglobin level (r = -0.41, P = .01), linking erythrocyte glutamine depletion to dysregulation of the arginine-NO pathway and increased hemolytic rate. Decreased erythrocyte glutathione and glutamine levels contribute to alterations in the erythrocyte redox environment, which may compromise erythrocyte integrity, contribute to hemolysis, and play a role in the pathogenesis of PH of SCD.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17848621      PMCID: PMC2200820          DOI: 10.1182/blood-2007-04-081703

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  92 in total

1.  Critical role of endothelial cell-derived nitric oxide synthase in sickle cell disease-induced microvascular dysfunction.

Authors:  Katherine C Wood; Robert P Hebbel; David J Lefer; D Neil Granger
Journal:  Free Radic Biol Med       Date:  2006-01-17       Impact factor: 7.376

2.  Accelerated autoxidation and heme loss due to instability of sickle hemoglobin.

Authors:  R P Hebbel; W T Morgan; J W Eaton; B E Hedlund
Journal:  Proc Natl Acad Sci U S A       Date:  1988-01       Impact factor: 11.205

3.  In vivo rates of erythrocyte glutathione synthesis in children with severe protein-energy malnutrition.

Authors:  M Reid; A Badaloo; T Forrester; J F Morlese; M Frazer; W C Heird; F Jahoor
Journal:  Am J Physiol Endocrinol Metab       Date:  2000-03       Impact factor: 4.310

4.  Optimization of folic acid, vitamin B(12), and vitamin B(6) supplements in pediatric patients with sickle cell disease.

Authors:  Fey P L van der Dijs; M Rebecca Fokkema; D A Janneke Dijck-Brouwer; Bram Niessink; Thaliet I C van der Wal; John-John B Schnog; Ashley J Duits; Fred D Muskiet; Frits A J Muskiet
Journal:  Am J Hematol       Date:  2002-04       Impact factor: 10.047

5.  New strategies for the treatment of pulmonary hypertension in sickle cell disease : the rationale for arginine therapy.

Authors:  Claudia R Morris
Journal:  Treat Respir Med       Date:  2006

6.  Hemolysis-associated priapism in sickle cell disease.

Authors:  Vikki G Nolan; Diego F Wyszynski; Lindsay A Farrer; Martin H Steinberg
Journal:  Blood       Date:  2005-06-28       Impact factor: 22.113

7.  N-terminal pro-brain natriuretic peptide levels and risk of death in sickle cell disease.

Authors:  Roberto F Machado; Anastasia Anthi; Martin H Steinberg; Duane Bonds; Vandana Sachdev; Gregory J Kato; Angelo M Taveira-DaSilva; Samir K Ballas; William Blackwelder; Xiuli Xu; Lori Hunter; Bruce Barton; Myron Waclawiw; Oswaldo Castro; Mark T Gladwin
Journal:  JAMA       Date:  2006-07-19       Impact factor: 56.272

8.  Differential gene expression in pulmonary artery endothelial cells exposed to sickle cell plasma.

Authors:  Elizabeth S Klings; Surinder Safaya; Adeboye H Adewoye; Adam Odhiambo; Garrett Frampton; Marc Lenburg; Norman Gerry; Paola Sebastiani; Martin H Steinberg; Harrison W Farber
Journal:  Physiol Genomics       Date:  2005-03-01       Impact factor: 3.107

9.  Divergent nitric oxide bioavailability in men and women with sickle cell disease.

Authors:  Mark T Gladwin; Alan N Schechter; Frederick P Ognibene; Wynona A Coles; Christopher D Reiter; William H Schenke; Gyorgy Csako; Myron A Waclawiw; Julio A Panza; Richard O Cannon
Journal:  Circulation       Date:  2003-01-21       Impact factor: 29.690

10.  Oxidative stress in severe pulmonary hypertension.

Authors:  Rebecca Bowers; Carlyne Cool; Robert C Murphy; Rubin M Tuder; Matthew W Hopken; Sonia C Flores; Norbert F Voelkel
Journal:  Am J Respir Crit Care Med       Date:  2003-12-30       Impact factor: 21.405

View more
  68 in total

1.  Possible links between sickle cell crisis and pentavalent antimony.

Authors:  Daniel Garcerant; Luisa Rubiano; Victor Blanco; Javier Martinez; Nancy C Baker; Noah Craft
Journal:  Am J Trop Med Hyg       Date:  2012-06       Impact factor: 2.345

2.  Dysregulated arginine metabolism and cardiopulmonary dysfunction in patients with thalassaemia.

Authors:  Claudia R Morris; Hae-Young Kim; Elizabeth S Klings; John Wood; John B Porter; Felicia Trachtenberg; Nancy Sweeters; Nancy F Olivieri; Janet L Kwiatkowski; Lisa Virzi; Kathryn Hassell; Ali Taher; Ellis J Neufeld; Alexis A Thompson; Sandra Larkin; Jung H Suh; Elliott P Vichinsky; Frans A Kuypers
Journal:  Br J Haematol       Date:  2015-04-24       Impact factor: 6.998

3.  The proverbial chicken or the egg? Dissection of the role of cell-free hemoglobin versus reactive oxygen species in sickle cell pathophysiology.

Authors:  Megan L Krajewski; Lewis L Hsu; Mark T Gladwin
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-05-23       Impact factor: 4.733

Review 4.  Measuring success: utility of biomarkers in sickle cell disease clinical trials and care.

Authors:  Ram Kalpatthi; Enrico M Novelli
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

5.  Nonhematopoietic Nrf2 dominantly impedes adult progression of sickle cell anemia in mice.

Authors:  Samit Ghosh; Chibueze A Ihunnah; Rimi Hazra; Aisha L Walker; Jason M Hansen; David R Archer; Amma T Owusu-Ansah; Solomon F Ofori-Acquah
Journal:  JCI Insight       Date:  2016-04-07

6.  Novel small molecule therapeutics for sickle cell disease: nitric oxide, carbon monoxide, nitrite, and apolipoprotein A-I.

Authors:  Gregory J Kato
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2008

7.  Antisickling property of fetal hemoglobin enhances nitric oxide bioavailability and ameliorates organ oxidative stress in transgenic-knockout sickle mice.

Authors:  Trisha Dasgupta; Mary E Fabry; Dhananjay K Kaul
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2009-12-09       Impact factor: 3.619

Review 8.  Pleiotropic effects of intravascular haemolysis on vascular homeostasis.

Authors:  Gregory J Kato; James G Taylor
Journal:  Br J Haematol       Date:  2009-12-01       Impact factor: 6.998

9.  Hematologic, biochemical, and cardiopulmonary effects of L-arginine supplementation or phosphodiesterase 5 inhibition in patients with sickle cell disease who are on hydroxyurea therapy.

Authors:  Jane A Little; Kristine Partovi Hauser; Sabrina E Martyr; Amy Harris; Irina Maric; Claudia R Morris; Jung H Suh; James Taylor; Oswaldo Castro; Roberto Machado; Gregory Kato; Mark T Gladwin
Journal:  Eur J Haematol       Date:  2008-02-10       Impact factor: 2.997

10.  Clinical assay of four thiol amino acid redox couples by LC-MS/MS: utility in thalassemia.

Authors:  Jung H Suh; Robert Kim; Burcu Yavuz; Daniel Lee; Ashutosh Lal; Bruce N Ames; Mark K Shigenaga
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2009-07-02       Impact factor: 3.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.